Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation.
Yang Liu,Xin Chen,Feng Wang,Yingcong Liang,Hai Deng,Hongtao Liao,Qianhuan Zhang,Bin Zhang,Xianzhang Zhan,Xianhong Fang,Michael Shehata,Xunzhang Wang,Yumei Xue,Shulin Wu
DOI: https://doi.org/10.1002/mgg3.638
2019-01-01
Molecular Genetics & Genomic Medicine
Abstract:BackgroundCardiac involvement in Danon disease typically manifests as left ventricular hypertrophy (LVH) and ventricular preexcitation. This study aimed to identify patients with Danon disease among patients with LVH and concurrent electrocardiographic preexcitation. MethodsElectrocardiographic preexcitation was identified in 10 of 197 patients with unexplained LVH in whom genetic testing was performed using next-generation sequencing. ResultsThree (3/10, 30%) patients with Danon disease were found in association with different mutations in the gene of lysosome-associated membrane protein 2 (LAMP2). Compared to seven patients without Danon disease, these three patients presented with distinctive clinical phenotypes, including onset at an earlier age (202years vs. 53 +/- 9years, p<0.001), more neurological involvements (100% vs. 0, p=0.008), higher electrocardiographic voltages (10 +/- 1mV vs. 5 +/- 1mV, p<0.001), wider QRS complexes (163 +/- 5ms vs. 115 +/- 20ms, p=0.006), less common asymmetric hypertrophy (0% vs. 86%, p=0.033), and more frequent elevation of three serum enzymes (creatine kinase, aspartate aminotransferase, and lactate dehydrogenase). Intracellular vacuoles accumulation with deficiencies of LAMP2 protein was found in both cardiac and skeletal myocytes of patients with Danon disease. ConclusionIn patients with coexistent LVH and ventricular preexcitation, Danon disease is common with distinctive clinical presentations. Comprehensive assessment of these resemble patients can provide valuable findings for early identification and clinical decision making of patients with Danon disease.